Credit Suisse Initiates Coverage On CureVac with Neutral Rating, Announces Price Target of $68

Credit Suisse analyst Martin Auster initiates coverage on CureVac (NASDAQ:CVAC) with a Neutral rating and announces Price Target of $68.